aiwiki.page
English
Health / Diseases & Symptoms / non-hodgkin-lymphoma

Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma encompasses diverse B-cell, T-cell, and natural killer-cell cancers with distinct biological features, clinical courses, and treatments.

52 keywords6 linked from6 not yet writtenWritten by AI
LymphomaImmune SystemT CellHodgkin LymphomaCancerPathologyWorld Health Org…Diffuse Large B-…Non-Hodgki…

Non-Hodgkin lymphoma (NHL) is a collective term for a diverse group of lymphomas arising from lymphocytes, cells that participate in the immune system. These malignancies may develop in lymph nodes, bone marrow, or almost any organ. They range from slowly progressive disorders that can remain asymptomatic for years to rapidly growing cancers requiring prompt treatment. Most arise from B lymphocytes; smaller groups originate from T lymphocytes or natural killer cells.

The term distinguishes these diseases from Hodgkin lymphoma, but it does not denote a single biological entity. Modern classification identifies individual diseases through tissue architecture, cellular appearance, immunologic markers, genetic alterations, and clinical context. Consequently, prognosis and treatment depend much more on the specific lymphoma type than on the label “non-Hodgkin.”

NHL is important both as a major category of cancer and as a model of how disrupted immune-cell development produces malignancy. Advances in tissue diagnosis, combination chemotherapy, antibody treatment, molecularly targeted drugs, and engineered immune cells have substantially altered its management. Some forms are frequently curable, while others typically follow a relapsing course that can extend over many years.

Classification and the meaning of the term

“Non-Hodgkin lymphoma” is a historical umbrella rather than a single diagnosis in contemporary pathology. The classification systems developed by the World Health Organization and the International Consensus Classification divide lymphoid malignancies into defined entities. The fifth edition of the WHO classification and the International Consensus Classification, both introduced in 2022, share many principles but differ in some names, boundaries, and groupings. A complete diagnosis therefore identifies an entity rather than merely reporting NHL.

The largest division is by cell lineage. B-cell lymphomas account for roughly 85–90% of NHL in many Western populations, although the proportion varies geographically. Mature B-cell diseases include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphomas, and Burkitt lymphoma. Chronic lymphocytic leukemia and small lymphocytic lymphoma represent blood-predominant and tissue-predominant manifestations of the same disease. This illustrates why the boundary between lymphoma and leukemia is partly anatomical rather than an absolute biological distinction.

T-cell and natural killer-cell neoplasms form a smaller, particularly heterogeneous group. Examples include peripheral T-cell lymphoma, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, and extranodal NK/T-cell lymphoma. Cutaneous T-cell lymphomas, including mycosis fungoides and Sézary syndrome, have characteristic skin manifestations. Precursor lymphoblastic lymphomas arise from immature lymphoid cells and are closely related to acute lymphoblastic leukemia; they are generally treated using leukemia-type regimens.

A second, clinically useful distinction concerns tempo. Indolent lymphomas, such as many follicular and marginal zone lymphomas, often grow slowly but may relapse repeatedly. Aggressive lymphomas, including DLBCL, grow more rapidly but can be eradicated by treatment. Burkitt lymphoma is exceptionally fast-growing, yet it is also potentially curable. These categories are useful shorthand, not substitutes for an entity-specific diagnosis: behavior varies within each group, and an indolent lymphoma can transform into an aggressive one.

The distinction from Hodgkin lymphoma also requires more than finding or excluding a particular large cell. Classical Hodgkin lymphoma has characteristic tumor cells, a distinctive inflammatory background, and an associated immunophenotype. Several non-Hodgkin entities can resemble it morphologically. Modern classification therefore integrates appearance with marker expression, genetics, and disease distribution rather than relying on a simple “Hodgkin versus non-Hodgkin” split.

Cellular origins and molecular mechanisms

Normal lymphocytes undergo unusually extensive genetic modification during development. B cells assemble antibody genes through V(D)J recombination and, after antigen stimulation, may undergo somatic hypermutation and class-switch recombination. These mechanisms generate immune diversity but also create opportunities for erroneous DNA repair. A mutation or chromosomal rearrangement can activate a growth-promoting gene, disable a tumor-suppressor pathway, or prevent a damaged cell from dying.

Several characteristic rearrangements illustrate these mechanisms. In most conventional follicular lymphomas, the t(14;18)t(14;18) translocation places BCL2 under the influence of immunoglobulin regulatory elements. Increased BCL2 activity inhibits apoptosis, allowing abnormal B cells to survive. Most mantle cell lymphomas carry t(11;14)t(11;14), which increases cyclin D1 expression and disturbs cell-cycle control. Burkitt lymphoma typically has a MYC rearrangement, most often t(8;14)t(8;14), promoting rapid cellular growth. None of these examples implies that one alteration alone explains every case.

DLBCL demonstrates the molecular diversity concealed within a single morphological label. Gene-expression studies distinguish germinal-center B-cell-like and activated B-cell-like groups, among others. These differ in signaling dependencies and average outcomes. Further genomic classifications identify combinations of mutations affecting B-cell receptor signaling, NF-κB activity, chromatin regulation, and immune recognition. High-grade lymphomas with particular combinations of MYC and BCL2 rearrangements form a clinically important category, but precise classification depends on the system used and the complete pathological findings.

The surrounding tissue also contributes to lymphoma biology. Malignant cells interact with T cells, macrophages, stromal cells, and follicular dendritic cells. Signals from these neighboring cells can support survival, supply growth factors, or suppress antitumor immunity. Conversely, some therapies work partly by recruiting immune cells rather than directly poisoning the lymphoma. The importance of this microenvironment helps explain why genetically abnormal cells do not behave identically in every tissue.

Infection provides several distinct routes to lymphomagenesis. Epstein–Barr virus can promote survival and proliferation of infected lymphocytes, especially when immune surveillance is impaired. Human T-lymphotropic virus type 1 is causally associated with adult T-cell leukemia/lymphoma. In contrast, Helicobacter pylori usually promotes gastric MALT lymphoma indirectly through sustained immune stimulation. These mechanisms differ from ordinary person-to-person transmission of an infection: lymphoma itself is not contagious, and infection with an associated organism usually does not lead to lymphoma.

Epidemiology and established risk factors

NHL occurs worldwide, but its frequency and subtype distribution vary substantially. The International Agency for Research on Cancer estimated approximately 553,000 new cases and 251,000 deaths globally in 2022. These aggregate figures combine diseases with markedly different ages of onset and outcomes. International comparisons also depend on access to tissue sampling, specialist pathology, and cancer registration; differences in recorded incidence do not necessarily reflect biological differences alone.

Most adult NHL becomes more common with advancing age, and many populations show a higher incidence in males. DLBCL is the most common aggressive adult subtype in many regions. Follicular lymphoma accounts for a larger share of cases in North America and Europe than in many Asian populations. Some T-cell and natural killer-cell lymphomas are relatively more frequent in parts of Asia and Latin America. Burkitt lymphoma has several epidemiological settings, including childhood disease in regions of equatorial Africa, where Epstein–Barr virus and malaria-related immune effects are important.

Impaired immune surveillance is an established risk context. HIV infection increases the risk of several aggressive B-cell lymphomas, including DLBCL, Burkitt lymphoma, and primary central nervous system lymphoma. Effective antiretroviral treatment has changed their incidence and outcomes. Recipients of organ transplants can develop post-transplant lymphoproliferative disorders under immunosuppression. These range from proliferations associated with Epstein–Barr virus to overt lymphomas, and their classification reflects the immune-deficiency setting.

Chronic immune stimulation is associated with selected subtypes rather than with all NHL equally. Sjögren disease is associated particularly with marginal zone lymphoma, and celiac disease is associated with enteropathy-associated T-cell lymphoma. Rheumatoid arthritis is also associated with increased lymphoma risk, with disease-related inflammation contributing to that relationship. Certain infections have specific associations: hepatitis C with some B-cell lymphomas, human herpesvirus 8 with primary effusion lymphoma, and H. pylori with gastric MALT lymphoma.

Family studies show that inherited susceptibility contributes to risk, but most cases are not explained by a single inherited mutation. Some rare immune-deficiency syndromes carry substantial lymphoma risk. Associations with occupational and environmental exposures have also been investigated, but findings depend on the substance, exposure level, and lymphoma subtype; broad claims that one exposure causes NHL as a whole are generally misleading. For most affected individuals, no single cause is identified. There is no established population-wide screening program for asymptomatic people at average risk.

Clinical manifestations and patterns of spread

The most familiar presentation is persistent, usually painless enlargement of a lymph node. Nodes may be noticed in the neck, armpit, or groin, while deeper enlargement is detected through symptoms or imaging. Lymphoma differs from many solid tumors in that lymphoid cells normally circulate and occupy multiple organs. Disease may therefore be widespread at diagnosis without following the orderly sequence of local invasion and distant spread typical of some other cancers.

Systemic manifestations include fever, drenching night sweats, and unintended weight loss. In lymphoma terminology, “B symptoms” have defined meanings: unexplained fever above 38∘C38^\circ\mathrm{C}, drenching night sweats, or loss of more than 10% of body weight over six months. These symptoms are not specific to lymphoma and can occur with infections and inflammatory disorders. Fatigue, itching, reduced appetite, and impaired physical functioning may occur but do not by themselves constitute the formal B-symptom category.

Extranodal disease produces symptoms according to the affected organ. Gastric or intestinal lymphoma can cause pain, bleeding, obstruction, or, less commonly, perforation. Disease in the chest may produce cough, breathlessness, or compression of major vessels. Involvement of the spleen can cause enlargement and abdominal fullness. Bone marrow infiltration may lead to anemia, low platelet counts, or reduced normal white blood cells. Some lymphomas circulate in the blood, while others remain predominantly nodal or extranodal.

Certain subtypes have recognizable patterns. Primary mediastinal large B-cell lymphoma often presents as a bulky chest mass in younger adults. Mantle cell lymphoma frequently involves multiple nodal and extranodal sites, including the gastrointestinal tract. Cutaneous lymphomas can produce patches, plaques, nodules, or widespread redness. Primary central nervous system lymphoma affects the brain, spinal cord, eyes, or associated compartments and may cause focal neurological deficits, cognitive changes, or visual symptoms.

Tempo is diagnostically informative but not definitive. An indolent lymphoma may produce fluctuating lymph-node enlargement over years, whereas an aggressive lymphoma can enlarge substantially over weeks. Sudden acceleration, new systemic symptoms, or disproportionate growth at one site can indicate transformation of an indolent disease, although tissue confirmation is needed. Acute complications include organ compression, spinal cord compression, intestinal obstruction, and tumor lysis syndrome. The latter results from rapid release of intracellular contents and can occur spontaneously in highly proliferative disease or after effective treatment.

Tissue diagnosis and laboratory characterization

A definitive diagnosis usually requires a biopsy that provides sufficient tissue for integrated examination. An excised lymph node often gives the most complete view of tissue architecture. A core-needle biopsy can establish the diagnosis in many situations, particularly for deep or difficult-to-access lesions, provided adequate material is obtained. Fine-needle aspiration alone is often insufficient for an initial lymphoma classification because individual cells do not reliably preserve the architectural relationships needed to distinguish many entities.

Histopathology establishes whether growth is follicular, diffuse, sinusoidal, or otherwise patterned, and assesses cell size, nuclear features, proliferation, and the surrounding inflammatory population. Immunohistochemistry then identifies proteins that clarify lineage and differentiation. CD20 and PAX5 commonly support B-cell lineage, while CD3 supports T-cell lineage. Other markers, including CD5, CD10, cyclin D1, BCL6, and ALK, help distinguish particular entities. No single marker panel is appropriate for every case, and no individual marker should be interpreted in isolation.

Flow cytometry rapidly measures multiple cellular markers and can demonstrate abnormal populations in tissue, blood, bone marrow, or body fluids. In B-cell disease, restricted expression of one immunoglobulin light chain often supports clonality. T-cell neoplasms may show abnormal loss or combinations of markers, but their interpretation can be more difficult. Molecular clonality testing can provide additional evidence, although clonality is not synonymous with malignancy and must be interpreted alongside morphology and clinical findings.

Genetic studies resolve important diagnostic and therapeutic questions. Fluorescence in situ hybridization detects selected rearrangements, such as those involving MYC, BCL2, or CCND1. Sequencing can identify mutations that support a diagnosis or reveal a treatment target. Epstein–Barr virus-encoded RNA testing can establish viral involvement within tumor cells. The proliferation marker Ki-67 estimates the proportion of dividing cells; a high value can support recognition of a rapidly proliferating tumor, but it neither defines a subtype by itself nor determines an individual outcome.

Blood investigations characterize disease effects and treatment-relevant conditions rather than replacing tissue diagnosis. A complete blood count, kidney and liver tests, lactate dehydrogenase, and selected infection tests are commonly included. Lactate dehydrogenase is a nonspecific indicator of tissue turnover and contributes to several prognostic models. Important alternatives include reactive lymph-node enlargement, infection, autoimmune disease, metastatic carcinoma, and Hodgkin lymphoma. Expert hematopathology review can materially change classification when a rare or borderline entity is suspected.

Staging, risk assessment, and response measurement

Staging describes the anatomical distribution of lymphoma, while prognostic assessment estimates likely outcomes using additional clinical and biological information. The Ann Arbor framework, as adapted by the 2014 Lugano classification, remains central. Stage I generally indicates a single nodal region or a single localized extranodal site. Stage II involves two or more nodal regions on the same side of the diaphragm. Stage III involves nodes on both sides, and stage IV denotes disseminated extranodal involvement, such as diffuse bone marrow or liver disease.

These stages do not carry the same implications as stages in many solid cancers. Stage IV NHL is not automatically incurable: disseminated DLBCL and Burkitt lymphoma may still be treated with curative intent. Conversely, some widespread indolent lymphomas are managed as long-term relapsing diseases. Tumor bulk, involved organs, functional status, laboratory abnormalities, and precise subtype often influence treatment more directly than stage alone. Formal staging conventions also differ for some extranodal diseases.

For most fluorodeoxyglucose-avid lymphomas, positron emission tomography combined with computed tomography maps metabolically active disease and establishes a baseline for response assessment. CT remains important for anatomical measurements and less consistently FDG-avid entities. Magnetic resonance imaging is particularly valuable for suspected central nervous system, spinal, or certain musculoskeletal involvement. Bone marrow biopsy is no longer universally necessary in every subtype; its value depends on the disease, imaging findings, and whether the result would change management.

The International Prognostic Index, developed for aggressive lymphomas, uses age, disease stage, serum lactate dehydrogenase, performance status, and the number of extranodal sites. Other models include the Follicular Lymphoma International Prognostic Index and the Mantle Cell Lymphoma International Prognostic Index. These instruments stratify groups of patients rather than predicting an individual’s course with certainty. Their performance also changes as treatment improves, and they do not replace entity-specific molecular information.

Response assessment distinguishes complete response, partial response, stable disease, and progressive disease. For FDG-avid lymphoma, the Deauville five-point scale compares residual uptake with reference tissues, particularly the mediastinal blood pool and liver. A residual mass can represent scar tissue rather than viable lymphoma. Conversely, FDG uptake can reflect infection or inflammation, so an abnormal scan does not always establish persistent malignancy. New research using circulating tumor DNA aims to measure residual disease more sensitively, but its routine role remains dependent on subtype and clinical setting.

Initial treatment according to lymphoma subtype

There is no single standard treatment for all NHL. Initial management depends on the pathological entity, anatomical extent, disease tempo, symptoms, organ function, and treatment goals. The major modalities include observation, radiation therapy, chemotherapy, antibodies, molecularly targeted agents, and combinations of these approaches. Surgery is primarily diagnostic or used for complications rather than serving as the principal treatment for most lymphomas.

For selected asymptomatic patients with low-burden indolent lymphoma, active surveillance can defer treatment without compromising overall survival compared with immediate treatment strategies studied in that setting. Surveillance is structured clinical follow-up, not an assumption that the disease is harmless. Localized follicular or marginal zone lymphoma may be treated with involved-site radiotherapy, sometimes with long-lasting disease control. Advanced symptomatic indolent B-cell disease is commonly treated with an anti-CD20 antibody, alone or with other agents. Some maintenance approaches prolong the interval before progression, although benefits and adverse effects vary.

For many patients with DLBCL, treatment has long centered on R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Rituximab is a monoclonal antibody directed against CD20. Polatuzumab vedotin, an antibody–drug conjugate targeting CD79b, has been incorporated with rituximab and cyclophosphamide, doxorubicin, and prednisone for selected previously untreated patients. Its use reflects randomized evidence and regulatory approvals, but the appropriate regimen still depends on the exact entity and clinical setting.

Burkitt lymphoma generally requires intensive, short-duration, multiagent treatment with attention to central nervous system disease and tumor lysis. Lymphoblastic lymphoma is treated with extended leukemia-type protocols, including central nervous system-directed components. Primary central nervous system lymphoma requires drugs that achieve effective concentrations within the central nervous system, particularly high-dose methotrexate-based regimens. Peripheral T-cell lymphomas follow different strategies from most B-cell lymphomas; brentuximab vedotin-containing treatment has an established role in selected CD30-positive disease, especially systemic anaplastic large cell lymphoma.

Some lymphomas have a treatment-relevant infectious or immune context. Eradication of H. pylori can induce regression of many localized gastric MALT lymphomas. Treatment of hepatitis C can produce lymphoma responses in selected associated indolent B-cell diseases. Post-transplant lymphoproliferative disorders may respond to carefully managed reduction of immunosuppression, often combined with antibody treatment or chemotherapy. These examples illustrate why identifying the specific biological setting can be as important as measuring tumor size.

Relapsed disease and newer therapeutic approaches

Relapse means lymphoma has returned after a response; refractory disease has not responded adequately or has progressed during treatment. Evaluation at relapse may include another biopsy because the disease can transform or because a new lesion may have another cause. The duration of the previous response, prior treatments, current pathology, organ function, and available therapeutic targets all influence subsequent management. A relapse of indolent lymphoma is not equivalent to relapse of an aggressive lymphoma, either biologically or prognostically.

For chemotherapy-sensitive relapsed aggressive B-cell lymphoma, high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has historically provided a potentially curative strategy. The stored stem cells restore blood formation after intensive treatment; they are not themselves the principal antitumor agent. Allogeneic transplantation additionally introduces a donor immune system with a potential graft-versus-lymphoma effect, but it carries risks including graft-versus-host disease and is used in selected circumstances.

CAR T-cell therapy has changed treatment for several relapsed B-cell lymphomas. A patient’s T cells are collected and genetically modified to express a chimeric antigen receptor, commonly targeting CD19, then expanded and reinfused after lymphodepleting treatment. Several products are used for large B-cell lymphoma, and some have indications in follicular or mantle cell lymphoma. Randomized trials have established particular CAR T-cell products as second-line options for selected large B-cell lymphomas that are refractory to initial treatment or relapse early.

Other immune therapies do not require individualized cell manufacture. A bispecific antibody can bind a lymphoma antigen, such as CD20, and CD3 on T cells, bringing the cells together to promote killing. Antibody–drug conjugates deliver a cytotoxic payload to antigen-bearing cells. These approaches have expanded options in relapsed disease, but activity depends on the target and lymphoma type. Important immune-mediated toxicities include cytokine release syndrome and, particularly with cellular therapies, immune effector cell-associated neurotoxicity syndrome.

Molecularly targeted drugs act on dependencies within particular lymphoma cells. Bruton tyrosine kinase inhibitors interfere with B-cell receptor signaling and have roles in several B-cell disorders, notably mantle cell and marginal zone lymphoma. EZH2 inhibition is relevant to selected follicular lymphomas, and BCL2-directed treatment is important in certain lymphoid diseases. Resistance can arise through target alteration, bypass signaling, loss of the targeted antigen, or changes in the tumor microenvironment. Consequently, treatment sequencing and combinations remain active subjects of clinical trials, rather than a single uniform pathway for all relapsed NHL.

Prognosis, treatment complications, and long-term outcomes

Prognosis varies more between lymphoma entities than the umbrella term NHL suggests. Population statistics combine curable aggressive diseases, long-lived indolent diseases, and uncommon entities with difficult treatment courses. In the United States, recent population-based estimates place five-year relative survival for NHL overall at approximately three quarters, but this is not an individual prediction. Relative survival compares observed survival with expected survival in a comparable general population and does not describe relapse, symptom burden, or treatment toxicity.

Many patients with DLBCL achieve durable remission after initial treatment, and the risk of recurrence generally declines with time. Indolent lymphomas can remain controlled for prolonged periods, sometimes through several successive treatments. Histological transformation, early progression after initial treatment, particular molecular abnormalities, and impaired functional status can identify groups with less favorable outcomes. Long survival does not necessarily mean permanent eradication, just as an aggressive initial presentation does not necessarily preclude cure.

Early treatment complications reflect both the lymphoma and its therapy. Chemotherapy can suppress marrow function, producing neutropenia, infection, bleeding, and anemia. Tumor lysis syndrome can cause electrolyte disturbances, kidney injury, and cardiac complications. Anti-CD20 antibodies can reactivate hepatitis B in susceptible individuals, while prolonged depletion of normal B cells may reduce antibody levels. Cellular and T-cell-engaging therapies have distinct inflammatory and neurological toxicities that differ from conventional chemotherapy adverse effects.

Late effects depend on cumulative exposure, age, and treatment field. Anthracyclines can cause cardiac injury; some chemotherapy and radiation exposures increase the risk of secondary malignancies. Treatment may affect fertility, endocrine function, peripheral nerves, and bone health. Certain patients experience persistent fatigue, cognitive symptoms, anxiety, or difficulty returning to employment. These outcomes are increasingly measured alongside disease control through quality-of-life and patient-reported assessments. Palliative care can address symptom burden alongside lymphoma-directed treatment and is not restricted to the final phase of illness.

Long-term follow-up distinguishes relapse surveillance from monitoring for treatment-related effects. Routine imaging practices vary by subtype and clinical context; more scans do not automatically improve outcomes and can produce false-positive findings and additional procedures. Research is testing whether molecular residual-disease measurements can identify recurrence earlier and, more importantly, whether acting on those measurements improves survival or reduces treatment burden. Another major question is how best to sequence transplantation, cellular therapy, bispecific antibodies, and targeted drugs while preserving immune function and limiting cumulative toxicity.